❤️ Bigeminy: Definition, Mechanism, Clinical Significance, and Management
---
## 🔹 1. Definition
**Bigeminy** is a cardiac rhythm pattern in which **every normal beat is followed by a premature beat** (usually ventricular or occasionally atrial).
It literally means *“occurring in twos.”*
### Types:
1. **Ventricular bigeminy** — normal sinus beat followed by a **premature ventricular complex (PVC)**.
→ The most common and clinically significant type.
2. **Atrial bigeminy** — normal sinus beat followed by a **premature atrial contraction (PAC)**.
→ Usually benign unless it triggers tachyarrhythmia in a vulnerable myocardium.
---
## 🔹 2. ECG Characteristics
### **Ventricular bigeminy**
* Every normal **QRS (narrow, sinus)** followed by a **premature wide QRS** (PVC).
* PVC often **without preceding P wave**.
* **Compensatory pause** after the PVC → total RR interval ≈ two sinus cycles.
* May be **unifocal** (same morphology) or **multifocal** (varying shapes).
### **Atrial bigeminy**
* Each sinus P wave is followed by an **early atrial premature P'** with a different morphology, usually followed by a narrow QRS.
---
## 🔹 3. Pathophysiology (Mechanism)
Premature beats originate from **ectopic foci** due to:
* Enhanced **automaticity**
* **Triggered activity** (after-depolarisations)
* **Re-entry circuits**
These are often provoked by:
* Myocardial irritation (ischaemia, reperfusion, mechanical stretch)
* Electrolyte disturbances (↓K⁺, ↓Mg²⁺)
* Hypoxia, acidosis
* Catecholamine excess (stress, inotropes)
* Drug toxicity (especially digoxin, tricyclics)
* Post-CPB inflammation or air/microemboli
* Structural heart disease or scarring
---
## 🔹 4. Common Clinical Contexts in Cardiac ICU
1. **After cardiopulmonary bypass:**
→ Myocardial reperfusion, electrolyte shifts, suction-induced trauma.
2. **After valve surgery / CABG:**
→ Common transient arrhythmia; usually self-limiting.
3. **With inotropes (especially dobutamine, adrenaline, isoprenaline):**
→ Beta-adrenergic stimulation → increased automaticity.
4. **During electrolyte disturbance:**
→ Hypokalaemia, hypomagnesaemia.
5. **In myocardial ischaemia or infarction.**
---
## 🔹 5. Clinical Significance
| Situation | Implication |
| ---------------------------------------------- | ----------------------------------------------------------------------- |
| **Isolated, asymptomatic** | Often benign; monitor & correct causes. |
| **Frequent PVCs (>6/min) or bigeminy pattern** | Can reduce stroke volume due to non-perfusing PVCs → ↓ CO, hypotension. |
| **In ischemic or LV-dysfunction patients** | May precede **ventricular tachycardia (VT) or VF** → warning sign. |
| **With haemodynamic instability** | Requires immediate management. |
---
## 🔹 6. Evaluation
### **A. Bedside**
* **Check leads & artefact** first.
* Assess **haemodynamics** (BP, pulse deficit).
* Look for **pulse alternans** — strong–weak pattern if many PVCs.
### **B. 12-lead ECG**
* Confirm morphology & coupling interval.
* Determine **unifocal or multifocal PVCs**.
* Look for **QT prolongation**, **ischemic changes**, **digoxin effect**.
### **C. Labs & Imaging**
* **Electrolytes:** K⁺, Mg²⁺, Ca²⁺
* **ABG:** Hypoxia, acidosis
* **Troponin:** if ischemic suspicion
* **Echocardiogram:** LV function, wall motion abnormalities
---
## 🔹 7. Management Approach
### 🩺 Step 1 – Identify & Correct Reversible Causes
* **Hypoxia:** Maintain PaO₂ 8–10 kPa, SpO₂ 92–96 %.
* **Acid–base:** Correct metabolic acidosis.
* **Electrolytes:**
* K⁺ ≥ 4.0 mmol/L
* Mg²⁺ ≥ 1.0 mmol/L
* Ca²⁺ within normal
* **Drug toxicity:** stop digoxin, tricyclics, sympathomimetics if implicated.
* **Ischaemia:** treat with O₂, nitrates, β-blockers, revascularisation if indicated.
### ⚙️ Step 2 – Evaluate Haemodynamic Impact
If **BP drop / poor CO / VF risk**:
* Treat **promptly**.
### ⚕️ Step 3 – Pharmacological Therapy
| Situation | Drug | Notes |
| ------------------------------------------------------------------- | ----------------------------------------------------------------------------- | ---------------------------------------------------------------- |
| **Symptomatic ventricular bigeminy with normal LV** | **β-blocker (metoprolol, esmolol)** | ↓ catecholamine effect; avoid in severe bradycardia or AV block. |
| **During inotrope use** | Try **reduce dose**, switch to **vasopressors (noradrenaline)** if possible. | |
| **Persistent or high-grade ventricular ectopy post-MI / ischaemia** | **Amiodarone 150 mg IV bolus**, then infusion (1 mg/min for 6 h → 0.5 mg/min) | Guideline-supported (AHA/ESC). |
| **Refractory / unstable → runs of VT** | **Lidocaine 1 mg/kg IV**, repeat q5 min to 3 mg/kg; infusion 1–4 mg/min | Avoid in severe LV dysfunction. |
Avoid class I agents (flecainide, propafenone) in structural heart disease.
### 🧰 Step 4 – Supportive Measures
* **Sedation & analgesia:** sympathetic surge worsens ectopy.
* **Pacing** rarely required unless bradycardia-triggered.
* **If recurrent with inotrope requirement:** consider **amiodarone infusion** as prophylaxis.
---
## 🔹 8. Special Cardiac-ICU Considerations
| Context | Typical Mechanism | Management Focus |
| ----------------------------------------- | --------------------------------- | -------------------------------------------------------------- |
| **After CABG** | Reperfusion / CPB irritation | Correct electrolytes, β-blocker, monitor for VF. |
| **After valve replacement (esp. aortic)** | LV hypertrophy, conduction trauma | Continuous ECG, consider temporary pacing if AV block appears. |
| **During dobutamine infusion** | β₁ overstimulation | Reduce dose or switch to noradrenaline. |
| **With poor LV EF (<35 %)** | Electrical instability | Continue amiodarone; avoid adrenaline surges. |
---
## 🔹 9. When to Escalate / Call for Urgent Help
* **Frequent PVCs (>10/min)** or bigeminy causing hypotension.
* **Runs of ≥3 PVCs (non-sustained VT)**.
* **Polymorphic or R-on-T PVCs** (risk of VF).
* **QT prolongation >500 ms**.
* **Associated chest pain / dynamic ECG changes**.
---
## 🔹 10. Prognosis
* **Benign in healthy hearts**, especially post-CPB transient ectopy.
* **Poor prognostic marker** if frequent in ischaemic cardiomyopathy or LV failure.
* **Resolution** usually within 24–48 h after correction of precipitating factors.
---
## 📚 Evidence-Based References
* **NICE NG196 (2021):** Acute coronary syndromes — arrhythmia management.
* **AHA 2022:** *Management of Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.*
* **ESC 2022 Ventricular Arrhythmia Guidelines.**
* **BJA Education (2020):** *Post-cardiac surgery arrhythmias.*
* **EACTS/EACTA 2021:** *Cardiac critical-care consensus.*
---
## ✅ **Quick Summary Table**
| Aspect | Ventricular Bigeminy | Atrial Bigeminy |
| --------------------- | -------------------------------------- | -------------------- |
| Origin | Ventricular ectopic focus | Atrial ectopic focus |
| QRS | Wide, bizarre | Narrow (usually) |
| P wave | Absent before ectopic | Early abnormal P' |
| Compensatory pause | Present | Usually incomplete |
| Clinical significance | May ↓ CO, warning for VT/VF | Usually benign |
| Management | Correct cause ± β-blocker / amiodarone | Observation |
---
## 🔹 Practical Bedside Approach for You (CTICU)
1️⃣ Recognise pattern → confirm with 12-lead ECG.
2️⃣ Assess **haemodynamics** and oxygenation.
3️⃣ **Check & correct K⁺/Mg²⁺/Ca²⁺**.
4️⃣ **Review inotropes** (reduce dobutamine/adrenaline if possible).
5️⃣ **Give β-blocker or amiodarone** if persistent or symptomatic.
6️⃣ **Monitor for VT/VF**; defibrillator nearby.
7️⃣ If recurrent → cardiology input, echo to assess LV function.
No comments:
Post a Comment